CAPA Commends New Bipartisan Effort To Address Big Pharma’s Patent Abuse

Thanks Representatives Spanberger and Reed for introducing legislation to stop the big drug companies from using patent thickets to abuse the patent system and hurt patients

WASHINGTON, D.C. – The Coalition Against Patent Abuse, a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free-market advocates and others released the following statement today in response to bipartisan legislation sponsored by U.S. Representatives Abigail Spanberger (D-VA) and Tom Reed (R-NY) that would bring needed transparency to Big Pharma’s use of patent thickets to prevent or delay competition from biosimilars, which are FDA-approved competitors to some of the most expensive biologic medicines. The following statements are attributable to Mathew Lane, Executive Director of the Coalition Against Patent Abuse.

“CAPA supports this new bipartisan effort by Representatives Spanberger and Reed and thanks them for their leadership on this important issue.  It is past time to rein in the big drug companies and prevent them from taking advantage of American patients.  The Biologic Patent Transparency Act is a crucial step toward addressing one of Big Pharma’s favorite dishonest tactics, patent thicketing.  This bill will provide much needed transparency into which patents protect older biologic medicines.”

“With ever-rising prescription drug costs and insurance premiums, Americans across the country are fed up with paying the price for Big Pharma’s greed and rampant patent abuse.  This bill demonstrates that there is growing bipartisan support for reforming the American drug system to ensure that patients are being put ahead of Big Pharma’s bank accounts.”

“We are grateful for the leadership of Representatives Spanberger and Reed and for their willingness to reach across the aisle to achieve results for American patients.  Our coalition is proud to support this legislation and looks forward to working together to rein in Big Pharma’s exploitation of the American patent system.  We hope to work in a bipartisan way on additional efforts to stop rampant patenting that is unnecessary for innovation and only drives up costs for patients and taxpayers.”

For more information, please visit